ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1406

Longitudinal Construct Validity of the Psaid Individual Items: Can We Eliminate Other Questionnaires If Using the Psaid?

Jessica Walsh1, Jose U. Scher2, Soumya M. Reddy3, M. Elaine Husni4 and Alexis Ogdie5, 1University of Utah School of Medicine, Salt Lake City, UT, USA, Salt Lake City, UT, 2New York University School of Medicine, New York, NY, 3Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 4Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, 5Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: outcome measures and psoriatic arthritis, Validity

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Session Title: Patient Outcomes, Preferences, and Attitudes Poster I: Patient-Reported Outcomes

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The Psoriatic Arthritis Impact of Disease (PsAID) questionnaire is a patient reported measure of disease impact. The 12-item questionnaire has many advantages including demonstrated validity, reliability, responsiveness and discrimination.  However, few studies have examined the use of individual items as surrogates for important patient reported outcomes. For example, we were interested in whether the single PsAID fatigue item could be used in place of the 13 item FACIT-F instrument.  Likewise, the pain, function, depression, and anxiety items could be used in place of additional questionnaires if the items correlated well with validated instruments both in cross-sectional and longitudinal settings. The objective of this study was to examine the longitudinal construct validity of the individual PSAID items for pain, fatigue, function, depression and anxiety.

Methods: Patients with PsA were enrolled in the Psoriatic Arthritis Research Consortium (PARC) between 2015-2017.  PARC is a longitudinal observational cohort at four institutions: University of Pennsylvania, Cleveland Clinic, New York University, and University of Utah. Two of these institutions (Utah and Penn) administered the PSAID.  Patient characteristics at the first/baseline visit were descriptively reported. The correlations were calculated among individual PSAID items with similar constructs (e.g., “tired” item with FACIT-F, BASDAI tired item, etc.) at baseline using Spearman’s correlation coefficients.  The change scores (e.g., score at visit 1 – score at visit 0) and the correlation among change scores between the individual items and related constructs were also calculated.

Results: PSAID data were available from 862 visits; 302 patients completed at least one PSAID and 208 patients completed PSAIDs at ≥2 visits.  Most patients were in low disease activity (mean 66/68 swollen and tender joint counts were 2.6 and 5.3, respectively).  At baseline, the mean PsAID9 and PsAID12 scores were 3.39 (SD 2.45) and 3.22 (2.40) respectively. The individual PsAID items were moderately correlated (rho= 0.5-0.8) with similar constructs at baseline.  However, aside from the moderate to strong correlation between the PsAID pain question with the RAPID3 pain question (rho=0.71), change scores were only slightly correlated with like instruments (rho = 0.2-0.45, Table).

Conclusion: The individual PsAID items did not correlate well with change in similar constructs over time. This may be due to the attribution of each symptom to PsA in the PSAID questionnaire.  The assessed PsAID items cannot be used as close substitutes for the validated questionnaires with which they were compared.


Disclosure: J. Walsh, Eli Lilly and Company, 5; J. U. Scher, Janssen, 5,Novartis, 5,UCB, Inc., 5,AbbVie Inc., 5; S. M. Reddy, Pfizer, Novartis, 5; M. E. Husni, None; A. Ogdie, Pfizer, Inc.; Novartis, 2,Abbvie, Amgen, BMS, Corrona, Lilly, Novartis, Pfizer, Takeda, 5.

To cite this abstract in AMA style:

Walsh J, Scher JU, Reddy SM, Husni ME, Ogdie A. Longitudinal Construct Validity of the Psaid Individual Items: Can We Eliminate Other Questionnaires If Using the Psaid? [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/longitudinal-construct-validity-of-the-psaid-individual-items-can-we-eliminate-other-questionnaires-if-using-the-psaid/. Accessed February 3, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/longitudinal-construct-validity-of-the-psaid-individual-items-can-we-eliminate-other-questionnaires-if-using-the-psaid/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences